NuStar GP (NSH) Stock Rating Upgraded by Zacks Investment Research

NuStar GP (NYSE:NSH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, June 20th.

According to Zacks, “NUSTAR GP HOLDINGS is a publicly traded limited liability company that owns the two percent general partner interest, a 18.4 percent limited partner interest and the incentive distribution rights in NuStar Energy L.P.They are one of the largest asphalt refiners and marketers and independent terminal and petroleum liquids pipeline operators in the nation with operations in the United States, Netherlands Antilles, Canada, Mexico, the Netherlands and the United Kingdom. “

A number of other brokerages have also recently commented on NSH. Barclays dropped their price objective on shares of NuStar GP from $15.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 17th. Mizuho restated a “hold” rating and issued a $13.00 price objective on shares of NuStar GP in a report on Wednesday, April 11th. ValuEngine raised NuStar GP from a “sell” rating to a “hold” rating in a research note on Wednesday, April 11th. B. Riley reaffirmed a “neutral” rating and issued a $14.00 target price (down from $20.00) on shares of NuStar GP in a research note on Tuesday, March 20th. Finally, Citigroup cut their price objective on NuStar GP from $15.00 to $12.00 and set a “neutral” rating for the company in a research report on Tuesday, May 1st. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and one has given a buy rating to the company. NuStar GP has an average rating of “Hold” and a consensus target price of $16.43.

NSH stock opened at $12.40 on Wednesday. NuStar GP has a one year low of $10.40 and a one year high of $25.25. The stock has a market cap of $545.51 million, a price-to-earnings ratio of 10.00 and a beta of 1.32.

NuStar GP (NYSE:NSH) last posted its quarterly earnings data on Thursday, April 26th. The pipeline company reported $0.28 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.33 by ($0.05). NuStar GP had a net margin of 174.77% and a return on equity of 21.96%. The company had revenue of $13.32 million for the quarter. equities research analysts predict that NuStar GP will post 0.2 EPS for the current year.

Hedge funds have recently made changes to their positions in the stock. Raymond James & Associates acquired a new position in NuStar GP during the fourth quarter worth $168,000. Stifel Financial Corp purchased a new stake in shares of NuStar GP in the first quarter valued at $227,000. Brown Advisory Inc. lifted its position in shares of NuStar GP by 70.0% in the fourth quarter. Brown Advisory Inc. now owns 17,000 shares of the pipeline company’s stock valued at $267,000 after acquiring an additional 7,000 shares in the last quarter. Susquehanna Fundamental Investments LLC purchased a new stake in shares of NuStar GP in the first quarter valued at $286,000. Finally, BB&T Securities LLC purchased a new stake in shares of NuStar GP in the first quarter valued at $309,000. 47.61% of the stock is currently owned by hedge funds and other institutional investors.

About NuStar GP

NuStar GP Holdings, LLC, through its ownership interests in NuStar Energy L.P., engages in the transportation of petroleum products and anhydrous ammonia. The company is also involved in the terminalling, storage, and marketing of petroleum products. It has pipelines in the United States; and terminal and storage facilities in the United States, Canada, Mexico, and the United Kingdom, as well as the Netherlands, including St.

Get a free copy of the Zacks research report on NuStar GP (NSH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for NuStar GP (NYSE:NSH)

Receive News & Ratings for NuStar GP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuStar GP and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply